Of 75 moderate-risk RET carriers offered surgery, only 20 (26.7%) proceeded, with 12 showing histologically confirmed medullary thyroid cancer, predominantly stage 1 disease (10 of 12 [83.3%]). This evidence concerns the gene RET and medullary thyroid gland carcinoma.